Welcome to our dedicated page for Amesite news (Ticker: AMST), a resource for investors and traders seeking the latest updates and insights on Amesite stock.
Amesite Inc. reports developments tied to its AI-native healthcare software business, centered on the NurseMagic platform and EMR for non-acute and post-acute care. Company updates cover product expansion, documentation and workflow tools, HIPAA-related connectivity, electronic visit verification interfaces, enterprise adoption, and customer-facing updates for home health, hospice, skilled nursing, senior living, and home care settings.
News about AMST also includes capital-structure actions such as registered direct offerings, private placements, warrants, registration-statement activity, and Nasdaq listing compliance matters. These items frame the company’s financing, governance, and public-company status alongside its healthcare AI platform strategy.
Amesite (Nasdaq: AMST) announced a new enterprise customer for its AI-native NurseMagic™ platform, covering an approximately 2,700-patient census, its largest deployment to date. The rollout aims to cut administrative work that can reach 16 hours per caregiver per week and integrates EMR and EVV workflows.
Amesite reports NurseMagic™ has supported an approximately 18% reduction in operating spend over six quarters while its digital funnel delivers about 4,200 web visits per day and a growing pipeline of enterprise opportunities in the non-acute/post-acute care market.
Amesite (Nasdaq: AMST) closed concurrent offerings that generated approximately $2.6 million of aggregate gross proceeds upfront and issued warrants that could provide an additional ~$5.2 million if fully exercised, for potential aggregate proceeds of up to $7.8 million.
The company issued common shares, pre-funded warrants and Series A-1 and A-2 warrants at a purchase and exercise price of $1.435; certain officers and directors purchased 418,118 shares. Warrants become exercisable upon stockholder approval and the company agreed to file resale registration covering unregistered securities.
Amesite (Nasdaq: AMST) entered insider-led definitive agreements to sell 418,118 shares and accompanying Series A-1 and A-2 warrants at $1.435 per share, expected to close on or about April 28, 2026. Aggregate gross proceeds to the company from this private placement are expected to be approximately $600,000.
The company said proceeds will be used for general corporate purposes, and that completion of concurrent offerings should restore stockholders' equity above $2.5 million to regain Nasdaq compliance.
Amesite (Nasdaq: AMST) announced concurrent registered direct and private placements to raise up to $6 million in aggregate proceeds: approximately $2 million upfront from share sales and up to $4 million if issued warrants are fully exercised. Each offering price is $1.435 per share or pre-funded warrant.
Warrants (Series A-1 and A-2) cover up to 696,866 shares each, have a $1.435 exercise price, staggered expirations, and require shareholder approval before exercisability; H.C. Wainwright is placement agent.
Amesite (NASDAQ: AMST) announced filing with the SEC to withdraw its Registration Statement on Form S-1 (No. 333-295187) filed April 20, 2026, and said it no longer intends to pursue the public offering described in that filing at this time. The Registration Statement was not declared effective and no securities were sold.
The company reiterated its AI healthcare product NurseMagic™, citing a target market of $330 billion and usage claims including reduction of documentation time from 20 minutes to 20 seconds, use by over 100 professions, and deployment across 50 states and 21 countries.
Amesite (Nasdaq: AMST) signed an Electronic Transactions Trading Partner Agreement enabling HIPAA-compliant connectivity between its NurseMagic™ EMR and a leading homecare technology platform that processes tens of billions in annual homecare billings. The integration supports standardized EVV transactions mandated by CMS and 21st Century Cures Act, letting providers transmit and receive EVV through existing infrastructure while using NurseMagic™’s AI workflows. Amesite also reported strong recent revenue growth: 69% QoQ in Q2 2026 and 63% growth after launching a census-based Enterprise subscription model.
Amesite (NASDAQ: AMST) said its AI healthcare platform NurseMagic™ was named a finalist in Nurse.org’s “Best of Nursing: AI Nursing Tool” award on March 4, 2026.
The company reported staged revenue acceleration: 2.4x QoQ after May 2025 launches, +82% and +69% in subsequent quarters, and 63% Enterprise growth; NurseMagic™ now scales to enterprise and launched an AI-native EMR in December 2025.
Amesite (NASDAQ: AMST) launched the AI-native NurseMagic EMR on Dec 19, 2025, expanding its NurseMagic platform from point-of-care to core post-acute care infrastructure.
The EMR supports coexistence with legacy systems or full replacement and the company expects to begin onboarding EMR customers in January 2026. Amesite reported strong recent growth: a 2.4x quarterly revenue increase after the May 2025 Teams+ launch, +82% revenue in Q4 after the July 2025 Enterprise tier, and a further +69% QoQ in Q1 FY2026. Website visits rose ~1,400% since January 2025. The release targets a U.S. post-acute market valued at $470B (2024) and projected to exceed $850B.
Amesite (NASDAQ: AMST) reported a 69% quarter-over-quarter revenue increase in Q2 2026 while reducing spending and expanding customers in post-acute healthcare. The company cited 82% and 69% QoQ revenue gains across the last two quarters, rising customer adoption of its NurseMagic™ AI platform, and high engagement with 6,500 daily explainer-video views and 28,000 daily website visitors. Amesite plans to launch what it describes as the first AI-powered EMR for post-acute care by 2026 and emphasized continued AI-driven product rollouts and operational discipline.
Amesite (NASDAQ: AMST), an AI-powered enterprise solutions developer, reported 63% revenue growth for its NurseMagic™ platform following the July 14, 2025 launch of its census-based Enterprise subscription model. The company announced that Enterprise sales have surpassed B2C sales, driven by post-acute care providers seeking scalable compliance solutions.
Amesite also launched an AI-powered automated form fill solution for government forms, specifically targeting the upcoming Centers for Medicare & Medicaid Services (CMS) mandate for Hospice Outcomes and Patient Evaluation (HOPE) assessment. The solution aims to help healthcare organizations auto-populate complex forms, reduce administrative time, and ensure full reimbursements in a market growing at a CAGR of 8%.